Reporting suspected adverse events after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V of the EU SmPC.
Adverse events should be reported. Please report adverse events at https://aereporting.astrazeneca.com.